Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Post by attila9on Jul 11, 2004 8:45pm

232 Views

Post# 7697536

NOBODY WANTS TO REMEMBER

Airjockey,but he warned you guys over & over again but nobody would listen.Now it's time to pay the piper & your all whining.Regardless of the vote this company is finished in it's present form.Only a total reorganization with new management will help but it will still take years before anything good will become of this dog.Ha Ha Ha Fools Gold!!!!!!!!!!!!!Rememeber me now???????

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity